GSK Wins FDA Approval for Nelkarmi, Targets £40bn Sales
GSK wins FDA approval for Nelkarmi and targets £40bn in sales alongside £1.9bn in cuts.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.